TABLE I.
Plasma MHPG Levels
| Subjects | Range of values (pmol/ml) |
|---|---|
| Groups | |
| General population (N = 142) | 4.2–38.1a |
| X-linked mental retardation (MB/KS; N = 51) | 8.1–36.0 |
| Sexual disorder clinic (N = 46) | 0.0b–21.7 |
| Mental retardation (TE; N = 271) | 7.0–49.0 |
| Gene-related or drug-induced reductions in MAO activity | |
| Clorgyline-treated depressed patients (N = 10)c | 1.8–4.3 |
| MAO-A/B deficiency (N = 5) | 0.1–0.4 |
| MAO-A deficiency (N = 2) | 1.1–2.1 |
| Selegiline-treated patients (N = 18)c | 2.6–8.7 |
a
Mean ± SD = 14.8 ± 0.8.
b
Two individuals with no MHPG peak on HPLC-EC.
c
Clorgyline used at doses which selectively inhibit MAO-A; selegiline at concentrations which inhibit both MAO-B (completely) and MAO-A (partially).